iOncologi

Executive Summary

iOncologi is a clinical-stage biotechnology company pioneering RNA-based immunotherapies for difficult-to-treat solid tumors. Leveraging an AI-driven design platform and proprietary delivery technologies, the company aims to reprogram systemic and intratumoral immunity to overcome resistance to checkpoint inhibitors. Founded in 2018 and based in San Diego, iOncologi is currently conducting Phase 1 clinical trials for its lead candidate, which targets multiple solid tumor indications. The company's approach combines computational biology with advanced RNA engineering to create potent, durable anti-tumor responses. With a focus on immuno-oncology, iOncologi addresses a significant unmet medical need in cancers that are refractory to existing therapies. Its platform has the potential to generate a pipeline of novel immunotherapies, offering a competitive advantage through rapid candidate design and improved delivery to tumor sites. The early-stage nature of the company presents both opportunity and risk, as clinical validation is still pending. However, the innovative strategy and growing interest in RNA therapeutics position iOncologi as a notable player in the biotech landscape.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1 safety and efficacy data readout for lead candidate60% success
• Q2 2027IND filing for second pipeline candidate targeting a new indication50% success
• TBDStrategic partnership or collaboration with a larger pharma company30% success